Quick Reference Chart

PEDS:

0.8 mg/kg q wk (max-dose 50 mg q wk)

Humira*

Adalimumab

PsO / PsA 18 yrs +

80 mg on Day 1 and then
40 mg on Day 8

40 mg q2 wks

TNF-α blocker

Remicade*

lnfliximab

PsO / PsA 18 yrs +

5 mg/kg IV wk 0, 2, and 6

5 mg/kg IV q8 wks

TNF-α blocker

Cimzia*

Certolizumab Pegol

PsO / PsA 18 yrs +

>90 kg: no loading dose

400 mg q2 wks

TNF-α blocker

≤90 kg: 400 mg at wk 0, 2 and 4

200 mg q2 wks

Bimzelx*

Bimekizumab

PsO / PsA 18 yrs +

320 mg at wk 0, 4, 8, 12, and 16

320 mg q8 wks (for patients ≥ 120 kg, consider 320 mg q4 wks after wk 16)

IL-17A and F antagonist

Cosentyx*

Secukinumab

PsA 2 yrs +
PsO 6 yrs +

300 mg SQ at wk 0, 1, 2, 3, and 4

300 mg SQ q4 wks

IL-17A antagonist

PEDS:

Dosage based on body weight and administered at wks 0, 1, 2, 3, and 4 and q4 wks
<50 kg = 75 mg | ≥50 kg = 150 mg

Taltz*

lxekizumab

PsA 18 yrs +
PsO 6 yrs +

160 mg at wk 0, then 80 mg at wk 2, 4, 6, 8, 10, and 12

80 mg q4 wks

IL-17A antagonist

PEDS:

>50 kg = 160 mg at wk 0 then 80 mg q4 wks | 25 to 50 kg = 80 mg at wk 0 then 40 mg q4 wks | <25 kg = 40 mg at wk 0 then 20 mg q4 wks

Siliq

Brodalumab

PsO 18 yrs +

210 mg at wk 0, 1, and 2

210 mg q2 wks

IL-17A receptor antagonist

Stelara*

Ustekinumab

PsA 6 yrs +
PsO 6 yrs +

≤100 kg: 45 mg at wk 0 and 4

45 mg q12 wks

IL-12 and IL-23 antagonist

>100 kg: 90 mg at wk 0 and 4

90 mg q12 wks

PEDS:

Weight-based dosing recommended at initial dose, 4 weeks later, then q12 weeks.
Less than 60 kg = 0.75 mg/kg | 60 kg to 100 kg = 45 mg | Greater than 100 kg = 90 mg

Tremfya*

Guselkumab

PsO / PsA 6 yrs + (weighing ≥40 kg)

100 mg at wk 0 and 4

100 mg q8 wks

IL-23 antagonist

llumya

Tildrakizumab

PsO 18 yrs +

100 mg at wk 0 and 4

100 mg q12 wks

IL-23 antagonist

Skyrizi*

Risankizumab

PsO / PsA 18 yrs +

150 mg at wk 0 and 4

150 mg q12 wks

IL-23 antagonist

Spevigo (GPP)

Spesolimab

12 yrs + (weighing ≥40 kg)

For treatment of flare: 900 mg IV
Not experiencing a flare: 600 mg SQ

For treatment of flare: Repeat in one week if flare persists
Not experiencing a flare: 300 mg SQ q4 weeks
(SQ use after IV dose for flare treatment: Initiate or reinitiate at 300 mg SQ q4 weeks; no loading dose req’d)

IL-36 receptor antagonist

Humira

Adalimumab

12 yrs +

Day 1: 160 mg (given in one day or split over 2 consecutive days); Day 15: 80 mg; Day 29: 40 mg q wk or 80 mg q2 wk

40 mg q wk or 80 mg q2 wks

TNF-α blocker

PEDS:

30 kg to <60 kg: Day 1: 80 mg; Day 8: 40 mg TNF-α blocker
>60 kg: Day 1: 160 mg (given in one day or split over 2 consecutive days);
Day 15: 80 mg; Day 29 and subsequent doses: 40 mg q wk or 80 mg q2 wks

PEDS:

30 kg to <60 kg: 40 mg q2 wks
>60 kg: 40 mg q wk or 80 mg q2 wks

Cosentyx

Secukinumab

12 yrs +

300 mg at wk 0, 1, 2, 3, and 4

300 mg q4 wks; if inadequate response 300 mg q2 wks may be considered

IL-17A antagonist

PEDS:

Dosage based on body weight and administered at wks 0, 1, 2, 3, and 4, then q4 wks
≥30 kg to <90 kg=150 mg
≥90 kg=300 mg

Bimzelx

Bimekizumab

18 yrs +

320 mg at wk 0, 2, 4, 6, 8, 10, 12, 14, and 16

320 mg q4 wks

IL-17A and F antagonist

Dupixent

Dupilumab

6 mos +

600 mg

300 mg SQ q2 wk

IL-4 receptor-α antagonist (inhibits IL-4 and IL-13)

PEDS 6m–5y:

5 to <15 kg = 200 mg q4 wks | 15 to <30 kg = 300 mg q4 wks

PEDS 6y–17y:

15 to <30 kg = 600 mg then 300 mg q4 wks | 30 to <60 kg = 400 mg then 200 mg q2 wks | ≥60 kg = 600 mg then 300 mg q2 wks

Ebglyss

Lebrikizumab

12 yrs + (weighing ≥40 kg)

500 mg at wk 0 and 2, then 250 mg q2 wks until 16 wks or later, when adequate clinical response is achieved

250 mg q4 wks

IL-13 antagonist

Adbry

Tralokinumab

12 yrs +

Adults: 600 mg

Adults: 300 mg q2 wks; after 16 wks, q4 wks may be considered for adults <100 kg who achieve clear or almost clear skin

IL-13 antagonist

PEDS 12y-17y:

300 mg

PEDS 12y-17y:

150 mg q2 wks

Nemluvio

Nemolizumab

12 yrs +

60 mg

30 mg q4 wks; for patients achieving clear or almost clear skin at 16 wks, 30 mg q8 wks recommended. Use with topical corticosteroids and/or topical calcineurin inhibitors. When the disease has sufficiently improved, discontinue use of topical therapies

IL-31 receptor antagonist

Dupixent

Dupilumab

18 yrs +

600 mg

300 mg q2 wks

IL-4 receptor-α antagonist (inhibits IL-4 and IL-13)

Nemluvio

Nemolizumab

18 yrs +

60 mg

Adults weighing ≥90 kg: 60 mg q4 wks
Adults weighing <90 kg: 30 mg q4 wks

IL-31 receptor antagonist

Xolair

Omalizumab

12 yrs +

None

150 mg or 300 mg q4 wks

anti-IgE antibody

Dupixent

Dupilumab

12 yrs +

600 mg

300 mg q2 wks

IL-4 receptor-α antagonist (inhibits IL-4 and IL-13)

PEDS:

30 to <60 kg = 400 mg | ≥60 kg = 600 mg

PEDS:

30 to <60 kg = 200 mg q2 wks | ≥60 kg = 300 mg q2 wks

Dupixent

Dupilumab

18 yrs +

600 mg

300 mg q2 wks; use in combination with tapering course of oral corticosteroids

IL-4 receptor-α antagonist (inhibits IL-4 and IL-13)